logo-loader

ValiRx PLC to present at leading US cancer conference

Published: 03:24 31 Mar 2016 EDT

cancercell_56fcd117a0053
The firm is developing a drug for prostate cancer.

Shares in ValiRx PLC (LON:VAL) rose 2% after the life sciences specialist said it would be presenting research data at a leading oncology get-together in the US next month.

The American Association for Cancer Research Annual Conference will take place in New Orleans, starting April 16.

As well as presenting, the AIM-listed firm will use the event, which attracted 20,000 healthcare professionals last year, to promote its “products, therapeutics and services” to specialists.

In particular it will use the opportunity to further publicise the “excellent results” being seen in the clinical trial of VAL201 for difficult to prostate cancer.

"This is another great opportunity for us to show the excellence of our technology and products in a large international arena," said ValiRx chief executive Satu Vainikka.

At 8.20am, the shares were up 0.15p at 8.4p – a rise of almost 2%.

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

19 minutes ago